The BioHIT group of SKEL | The AI Lab organises an online talk on Thursday 30 September at 14.30, entitled The genomic aetiology of osteoarthritis.
Osteoarthritis is one of the leading causes of disability and pain worldwide, with over 300 million people affected. Currently no curative treatments are available. A detailed understanding of disease aetiopathology and novel drug targets are therefore urgently needed. In this talk, I will give an overview of how we have used translational genomics approaches to enhance our understanding of the genetic aetiology of osteoarthritis, shed novel biological insights, and provide a stepping stone for translating genetic associations into osteoarthritis drug development.
Eleftheria Zeggini obtained a BSc in Biochemistry and a PhD in Immunogenetics of Juvenile Arthritis from the University of Manchester. Following a statistical genetics post doc at the Centre for Integrated Genomic and Medical Research in Manchester, she moved to the Wellcome Trust Centre for Human Genetics in Oxford to undertake a post doc in type 2 diabetes research. In 2008, she joined the Wellcome Sanger Institute Human Genetics Faculty where she built a programme of work to advance analytical genomics of complex traits. In 2018, she moved to the Helmholtz Center Munich as founding Director of the Institute of Translational Genomics and since May 2020 holds the TUM Liesel Beckmann Distinguished Professorship at the Technical University Munich School of Medicine. Her research leverages big biomedical data and aims to translate insights from genomics into mechanisms of disease development and progression, shortening the path to translation and empowering precision medicine.